1
|
Meng L, Laber D, Cao B, Shafique M. EP14.01-013 First-Line Chemotherapy vs Chemoimmunotherapy in Stage IV Large Cell Neuroendocrine Carcinoma of the Lung, a Retrospective Study. J Thorac Oncol 2022. [DOI: 10.1016/j.jtho.2022.07.949] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|
2
|
Sam C, Desai P, Laber D, Patel A, Visweshwar N, Jaglal M. Pegylated bovine carboxyhaemoglobin utilisation in a thrombotic thrombocytopenic purpura patient. Transfus Med 2017; 27:300-302. [DOI: 10.1111/tme.12407] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/16/2017] [Revised: 02/24/2017] [Accepted: 02/27/2017] [Indexed: 12/14/2022]
Affiliation(s)
- C. Sam
- Department of Hematology; University of South Florida Morsani College of Medicine; Tampa Florida USA
| | - P. Desai
- Department of Hematology; University of South Florida Morsani College of Medicine; Tampa Florida USA
| | - D. Laber
- Department of Hematology; University of South Florida Morsani College of Medicine; Tampa Florida USA
- Department of Hematology & Oncology; Moffitt Cancer Center; Tampa Florida USA
| | - A. Patel
- Department of Hematology; University of South Florida Morsani College of Medicine; Tampa Florida USA
- Department of Hematology & Oncology; Moffitt Cancer Center; Tampa Florida USA
| | - N. Visweshwar
- Department of Hematology; University of South Florida Morsani College of Medicine; Tampa Florida USA
| | - M. Jaglal
- Department of Hematology; University of South Florida Morsani College of Medicine; Tampa Florida USA
- Department of Hematology & Oncology; Moffitt Cancer Center; Tampa Florida USA
| |
Collapse
|
3
|
Khan MI, Taft B, Rasku MA, Laber D, Chesney J, Miller DM. A phase II trial of biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, interferon, and digoxin in melanoma matients. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.8573] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
8573 Background: Patients with stage IV metastatic melanoma have limited treatment options. Epidemiological studies have demonstrated that there is a lower death rate from breast cancer in patients who are on digoxin therapy (6%) when compared with patients who are not on digoxin therapy (34%). Recent in vitro studies have shown that digoxin inhibits growth and causes apoptosis in multiple cell lines including breast cancer cells (MCF-7), non-small cell lung cancer cells, HeLa cells, renal adenocarcinoma cells (TK-10), neuroblastoma cells, and prostate cancer cells. In addition digoxin enhances the efficacy of chemotherapy against melanoma cells in vitro. Consequently, the addition of digoxin may augment the cytotoxic effects of bio-chemotherapy against stage IV melanoma. Methods: Twenty-seven patients with stage IV melanoma without CNS metastasis with a median age of 51 years (25–69), were enrolled in this open label phase II clinical trial. ECOG performance status was 0 to 1. Patients had normal cardiac, pulmonary, renal and liver function tests. Patients received digoxin 0.25 mg daily throughout all cycles. Patients were hospitalized in ICU for 5 days to receive the therapy and supportive care. Treatment schedule: dacarbazine, IV, 800 mg/m2 on day 1; cisplatin, IV, 20 mg/m2 on days 1–4; vinblastine, IV, 1.2 mg/m2 on days 1–4; IL-2, IV over 24 hours, 9 M IU/m2 on days 1–4; interferon, SC, 5 MU/m2 on days 1–5. After completing 2 cycles (28 days per cycle) patients were evaluated for response by CT and/or FDG-PET imaging studies. Patients who experienced a SD, PR, or CR then completed 2 more cycles of this therapy. There was no treatment related mortality. Results: Seven patients achieved CR (25.9%), five patients had a PR (18.5%), and six patients had a SD (22.2%). The overall clinical benefit was 66.6%. Nine patients (33.3%) experienced progressive disease and were taken off the protocol. Eleven patients (40%) are alive and sixteen patients (60%) have died. Conclusions: Our preliminary data demonstrate that the addition of digoxin to bio-chemotherapy may have a synergistic effect on patients with melanoma. Accrual to this trial is on-going and final overall survival and progression free survival will be evaluated in the future. No significant financial relationships to disclose.
Collapse
Affiliation(s)
| | - B. Taft
- Brown Cancer Center, Louisville, KY
| | | | - D. Laber
- Brown Cancer Center, Louisville, KY
| | | | | |
Collapse
|
4
|
Miller DM, Bates P, Trent J, Sharma V, Thomas S, Barnhart K, Laber D. 295 NUCLEOLIN, A NOVEL TARGET FOR APTAMER-BASED ANTICANCER THERAPY. J Investig Med 2005. [DOI: 10.2310/6650.2005.00006.294] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
|
5
|
Bhupalam L, Jaggernauth S, Laber D. Successful treatment of a patient with unresectable olfactory neuroblastoma: A case report and literature review. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.5620] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
| | | | - D. Laber
- University of Louisville, Louisville, KY
| |
Collapse
|
6
|
Drummond AH, Beckett P, Brown PD, Bone EA, Davidson AH, Galloway WA, Gearing AJ, Huxley P, Laber D, McCourt M, Whittaker M, Wood LM, Wright A. Preclinical and clinical studies of MMP inhibitors in cancer. Ann N Y Acad Sci 1999; 878:228-35. [PMID: 10415734 DOI: 10.1111/j.1749-6632.1999.tb07688.x] [Citation(s) in RCA: 168] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
The role of matrix metalloproteinases in tumor angiogenesis and growth is now well recognized for models of both human and animal cancer. Clinical studies currently under way with the prototype matrix metalloproteinase inhibitor, marimastat, will establish whether inhibitors of these enzymes are of benefit in the treatment of different types of human cancer. On chronic therapy in humans, marimastat induces a reversible tendinitis that can also be detected in certain animal species. This paper compares the ability of broad-spectrum and various types of selective matrix metalloproteinase inhibitors to induce tendinitis and to exhibit anticancer effects in an animal cancer model. Under conditions in which both systemic exposure and inhibitor potency are controlled, selective inhibitors are less pro-tendinitic, but are weaker anticancer agents than broad-spectrum agents such as marimastat. The clinical relevance of these findings is discussed.
Collapse
Affiliation(s)
- A H Drummond
- British Biotech Pharmaceuticals Limited, Oxford, United Kingdom.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
7
|
Norvell LL, Gulden G, Hoiland K, Bendiksen K, Brandrud TE, Foss BS, Jenssen HB, Laber D. Macromycetes and Air Pollution. Bibliotheca Mycologica: Band 144. Mycologia 1993. [DOI: 10.2307/3760627] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
|